Psilocybin shown to aid in cancer-related mental health conditions Cancer is a modern chronic disease characterized by abnormal cells dividing uncontrollably. There are over 200 types of cancer, some of which may spread into other body tissues. Cancer is the leading cause of death in Canada, responsible for over 28 percent of all deaths. Researchers …
The Potential Role of Psychedelics in Cancer Treatment Read More »
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients. …
The Medical Research Future Fund Clinical Trials Activity Initiative has awarded $2.7M for Innovative Therapies for Mental Illness to a Monash University-led team, to evaluate the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression. Major Depressive Disorder (MDD) is, sadly, common, and results in the greatest global burden of disease. Although there are established treatments for …
Organization Presents a Memorandum of Regulatory Approval to Health Canada and the Canadian Government A Nanos Research Survey released in August by the Canadian Psychedelic Association (CPA) shows 82 percent of Canadians approve the use of psilocybin-assisted therapy for people suffering from an end-of-life illness and 78 percent would support a government that legalized psilocybin-assisted …
ATMA and SYNTAC Institute Collaborate to Submit a Group Application for Section 56 Exemption from Health Canada to Access Psychedelic Therapy ATMA Journey Centers Inc. (ATMA), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced today that it has submitted a Group Application for Section 56 Exemption to Health Canada on behalf of Canadians …
